Oncternal Therapeutics Inc (NAS:ONCT)
$ 0.5266 0 (0%) Market Cap: 1.56 Mil Enterprise Value: -12.83 Mil PE Ratio: 0 PB Ratio: 0.17 GF Score: 29/100

Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 Transcript

Apr 03, 2023 / 09:00PM GMT
Release Date Price: $15.8 (+0.65%)
Operator

Greetings, and welcome to Oncternal analyst and investor call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Richard Vincent, Chief Financial Officer. Thank you. You may begin.

Rich Vincent
Oncternal Therapeutics, Inc. - CFO

Thank you, [Doug]. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon is our President and CEO, Dr. James Breitmeyer. This afternoon, we issued a press release describing a strategic reprioritization of our pipeline and cash preservation strategy. Today's press release and a replay of today's call will be available on the Investor Relations section of Oncternal's website for at least the next 30 days.

Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events, such as our business and product development strategies. The timing of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot